Wellington Management Group’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.25M Sell
36,311
-2,513
-6% -$75.9K ﹤0.01% 1712
2026
Q1
$925K Buy
38,824
+1,922
+5% +$53.3K ﹤0.01% 1688
2025
Q4
$1.02M Sell
36,902
-1,086
-3% -$27.7K ﹤0.01% 1711
2025
Q3
$922K Buy
37,988
+721
+2% +$14.3K ﹤0.01% 1793
2025
Q2
$634K Buy
37,267
+3,636
+11% +$63.3K ﹤0.01% 1782
2025
Q1
$657K Sell
33,631
-1,938
-5% -$50.8K ﹤0.01% 1786
2024
Q4
$882K Sell
35,569
-3,427
-9% -$87.5K ﹤0.01% 1738
2024
Q3
$955K Sell
38,996
-4,112
-10% -$106K ﹤0.01% 1720
2024
Q2
$1.01M Buy
43,108
+10,155
+31% +$249K ﹤0.01% 1673
2024
Q1
$1.09M Buy
32,953
+12,037
+58% +$375K ﹤0.01% 1672
2023
Q4
$569K Buy
+20,916
New +$520K ﹤0.01% 1716
2021
Q1
Sell
-192,931
Closed -$15.8M 2097
2020
Q4
$15.8M Buy
192,931
+145,931
+310% +$7.18M ﹤0.01% 1085
2020
Q3
$1.16M Buy
+47,000
New +$1.17M ﹤0.01% 1517

Other funds holding BEAM

Wellington Management Group's BEAM Position: Q2 2026 in Review

Wellington Management Group reduced its Beam Therapeutics (BEAM) stake by 6.5% in Q2 2026, selling an estimated $75.9K and leaving 36,311 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1712.

Wellington Management Group first reported a position in BEAM in Q3 2020 and has held it in 13 quarters since. The position peaked at $15.8M in Q4 2020. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Wellington Management Group held 36,311 shares of Beam Therapeutics worth $1.25M as of Q2 2026.
  • Wellington Management Group sold 2,513 Beam Therapeutics shares in Q2 2026, an estimated $75.9K.
  • Beam Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1712 holding.
  • Wellington Management Group first reported a position in Beam Therapeutics in Q3 2020 and has held it in 13 quarters since.
  • Wellington Management Group's Beam Therapeutics position peaked at $15.8M in Q4 2020.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.